Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Health Research Projects

University of Toronto

$199,366.00

Development of a lead boron-containing ClpP inhibitor for AML therapy

FY 2016-17

Summary
Cancer continues to be one of the leading causes of death in the world. This disease is exceptionally complex, which is whyit is extremely important to evaluate different angles for therapeutic intervention. This area of modern science involves anumber of disciplines, of which chemistry and biology play central roles. While biologists continue to discover new moleculartargets that make cancer cell susceptible to treatment, chemists are busy using the results of these studies in order toprepare molecules that can kill cancer cells. The present grant proposal combines the efforts of a renowned cancerhematologist (Schimmer) and a well-known expert in synthetic chemistry (Yudin). Together, the Schimmer and Yudin labshad realized that some of the molecules recently prepared in the Yudin lab can be particularly effective in killing the cancercells under investigation in the Schimmer lab. As a proof of concept, the two teams were able to show that boron-containingmolecules developed by Yudin and his students are particularly well suited to attack proteins that are thought to be presentin leukaemia cells. We plan to capitalize on our exciting preliminary results and ensure that our molecules are translated intoa clinical asset. In the course of this study, we will also be able to evaluate the significance of our chosen target in cancertherapy. Encouragingly, we have been able to attract interest on behalf of well-known companies (Merck, AstraZeneca, andAnacor), who will help us in our search of effective anti-cancer therapeutics.
Program
Collaborative Health Research Projects
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
478459-2015
Name nom
Yudin, Andrei
Department département
Chemistry (St. George Campus)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2015
Award amount
199366
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
2 & 3
Nb partie
3
Application title
Development of a lead boron-containing ClpP inhibitor for AML therapy
Keyword
NSERC
Application summary
Cancer continues to be one of the leading causes of death in the world. This disease is exceptionally complex, which is whyit is extremely important to evaluate different angles for therapeutic intervention. This area of modern science involves anumber of disciplines, of which chemistry and biology play central roles. While biologists continue to discover new moleculartargets that make cancer cell susceptible to treatment, chemists are busy using the results of these studies in order toprepare molecules that can kill cancer cells. The present grant proposal combines the efforts of a renowned cancerhematologist (Schimmer) and a well-known expert in synthetic chemistry (Yudin). Together, the Schimmer and Yudin labshad realized that some of the molecules recently prepared in the Yudin lab can be particularly effective in killing the cancercells under investigation in the Schimmer lab. As a proof of concept, the two teams were able to show that boron-containingmolecules developed by Yudin and his students are particularly well suited to attack proteins that are thought to be presentin leukaemia cells. We plan to capitalize on our exciting preliminary results and ensure that our molecules are translated intoa clinical asset. In the course of this study, we will also be able to evaluate the significance of our chosen target in cancertherapy. Encouragingly, we have been able to attract interest on behalf of well-known companies (Merck, AstraZeneca, andAnacor), who will help us in our search of effective anti-cancer therapeutics.
University of Toronto - $199,366 Grant (2016-17) | Canada Spends